CLC Bio Developing Platform for Aarhus-led Prostate Cancer Study | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – CLC Bio will develop a bioinformatics platform for Aarhus University Hospital to support an interdisciplinary genomics study that seeks to develop new tools for predicting prostate cancer risk and aggressiveness.

The Danish company said today that it will develop a platform for analyzing microarray and next-generation sequencing data for the multi-partner study, which is funded with $4 million by the Danish Council for Strategic Research.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.